Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.63 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27050890 | 1.00 | GPR84 (0.63) | GPR84FFAR1FFAR4ACE2SPHK1 | |
| SCHEMBL25676070 | 0.91 | GPR84 (0.50) | GPR84FFAR1CA1 | |
| SCHEMBL25676077 | 0.91 | GPR84 (0.50) | GPR84FFAR1CA1 | |
| SCHEMBL4055686 | 0.91 | GPR84 (0.50) | GPR84FFAR1CA1 | |
| SCHEMBL7045666 | 0.86 | GPR84 (0.67) | GPR84FFAR1FFAR4CA1MAPT | |
| SCHEMBL27721493 | 0.83 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL637778 | 0.81 | CHRM1 (0.40) | GPR84FFAR1CA1 | |
| SCHEMBL25676073 | 0.81 | CHRM1 (0.40) | GPR84FFAR1CA1 | |
| SCHEMBL26811 | 0.81 | CHRM1 (0.40) | GPR84FFAR1CA1 | |
| Heptane SCHEMBL9063842 | 0.81 | CES2 (0.50) | GPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | GPR84 2887/4885FFAR1 1075/4885FFAR4 1552/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | GPR84 1994/4885FFAR1 2128/4885FFAR4 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.